Disc Medicine priced an upsized public offering of 6 million shares of its common stock. The shares are priced at $75.00 each.
The company expects gross proceeds of approximately $450 million, up from the initially proposed $350 million. Underwriters have a 30-day option to purchase up to an additional 900,000 shares.
The offering is expected to close on October 22, 2026. Disc Medicine plans to use the net proceeds to advance research and clinical development of its product candidates, support the potential commercialization of its lead drug, bitopertin, and fund working capital and other general corporate purposes.